RANKL expression in other bone tumours has been studied to determine its role as a reliable prognostic marker in predicting recurrence (Ghani et al., 2018) and the use of Denosumab in treating patients with RANKL expression (Heymann, 2012). The gene discussed is TNFSF11; the disease is bone neoplasm.